Roche Products Pty Limited
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-eight medicines developed by Roche are included in the World Health Organisation Model Lists of Essential medicines, among them antibiotics, antimalarials and chemotherapy.
Roche’s anti-cancer medicines include ten products approved for use in Australia: Avastin (bevacizumab), Erivedge (vismodegib), Gazyva (obinutuzumab), Herceptin (trastuzumab), Kadcyla (trastuzumab emtansine), MabThera (rituximab), Perjeta (pertuzumab), Tarceva (erlotinib), Xeloda (capecitabine), and Zelboraf (vemurafenib).
In 2014, Roche invested over 8.9 billion Swiss francs in research and development worldwide, including over $36 million (AUD) in pharmaceuticals in Australia. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
More information about Roche in Australia is available through www.roche-australia.com or Roche Medical Information on 1800 233 950.